Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google ...

The newly launched Global Energy Transition Forum aims to serve as an international focal point for renewables development ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

"It also needs to be evaluated for use with portable echocardiogram machines used in emergency ... the biggest positive impact with AI tools." Novo Nordisk almost doubles the scale of its R ...

During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is ...

Goa is making significant strides in healthcare with initiatives like the Cancer Screening Abhiyan, which has benefited ...

IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Medicare is preparing to negotiate prices on GLP-1 drugs such as Ozempic. Novo Nordisk investors could see the news put $14.3 billion in Medicare revenue at risk. Viking Therapeutics stock ...